N/A N=265 Colorectal Cancer: Screening vs. Non-Screening
Colorectal Cancer · Screening
Primary: Colorectal Cancer Stage (pTNM) — 46; 85 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=8 Translation of Colorectal Cancer Screening Guidelines to Practice: A System Intervention
Colorectal Cancer
Primary: Percent of Patients Receiving GI Consult for FOBT+ Results — 39; 47; 64; 51 percent patients receiving GI consult
N/A N=5,970 Increasing Colorectal Cancer Screening in a Safety-net Health System With a Focus on the Uninsured: Benefits and Costs
Colorectal Cancer
Primary: Colorectal Cancer Screening Participation, Defined as Completion of a Guaiac or Immunochemical Stool Occult Blood Test, Colonoscopy, Sigmoidoscopy, or Barium Enem…
N/A N=264 Colorectal Cancer Screening Assessment Study
Colorectal Cancer
Primary: Use of FOBT ColoCARE Home Kit — 14; 2; 14; 0 participants
N/A N=1,855 The Colorectal Breath Analysis (COBRA) Study
Colorectal Cancer · Colorectal Polyps · Colorectal Adenocarcinoma
Primary: Determine the Diagnostic Accuracy of the Proposed Breath Test for Detection of Colorectal Cancer in All Patients — 79; 86 percentage of true cases
Phase 2 N=20 Cellular Immune Augmentation in Colon and Rectal Cancer
Colon Cancer · Rectal Cancer
Primary: Participants Exhibiting Immune Response — 11 Participants
N/A N=11,016 Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Colorectal Neoplasms · Digestive System Diseases · Colonic Diseases
Primary: Sensitivity and Specificity of the Exact CRC Screening Test With Comparison to Colonoscopy, Both With Respect to Cancer. — 92.3; 73.8; 93.3; 73.3 percent
N/A N=41,193 Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Colorectal Cancer
Primary: FIT Completion — 10.4; 13.9 Model based percentage of participants — p=.05
N/A N=404 Interventions to Improve Colorectal Cancer Screening
Colorectal Neoplasms
Primary: Colorectal Cancer Screening — 127; 112 participants — p=0.01
Phase 2 N=83 S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer
Colorectal Cancer
Primary: Pathologic Complete Response Rate — 25 percentage of participants — p=0.18
N/A N=12 Studies in Patients With Low Anterior Resection Syndrome (LARS)
Anterior Resection Syndrome · Bowel Dysfunction
Primary: Change of Anorectal Pressure Assessed With the Fecobionics Device — 9.8 cmH2O
Phase 2 N=79 Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer
Colon Cancer · Precancerous Condition · Rectal Cancer
Primary: Change of a Spectral Biomarker for Colonic Carcinogenesis (Called Spectral Slope or SPEC) From Baseline to 3 Months. — 40.72; 37.54; 43.45; 37.52 micron^-1 — p=0.11
N/A N=14,263 Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study
Colorectal Cancer · Advanced Adenocarcinoma · Serrated Polyp
Primary: ColoSense Sensitivity for Colorectal Cancer (CRC) — 25; 2 Participants
Phase 2 N=27 Regorafenib in Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Number of Subjects Who Experience Grade 3-5 Toxicity as a Measure of Safety and Tolerability. — 20 Participants
Phase 2 N=124 Efficacy of Delayed Coloanal Anastomosis for Medium and Lower Rectum Cancer Treatment. Phase 2 Clinical Trial (CASCADOR)
Medium and Lower Rectal Cancer
Primary: Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among 2SCA — 1 Participants
Phase 2 N=13 Genistein in Treatment of Metastatic Colorectal Cancer
Colon Cancer · Rectal Cancer · Colorectal Cancer
Primary: Number of Adverse Events — 250; 119; 24; 0 events
Phase 2 N=75 Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer
Colon Cancer · Colorectal Cancer
Primary: Maximum Tolerated Dose (MTD) of Celebrex in Combination With EPO906 — 9 mg/m2
Phase 2 N=17 Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery
Colorectal Cancer
Primary: Progression-free Survival (PFS) — 55 Days
Phase 2 N=221 Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Colorectal Cancer
Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004
N/A N=35 Fiber and Fish Oil Supplements for the Prevention of Colorectal Cancer
Healthy Subject
Primary: Feasibility and Retention for a Trial With Daily Doses of 35 g of Fiber and 6.2 g of EPA +DHA (and Corresponding Comparators) — 14; 15; 1; 1 Participants
Phase 2 N=24 Trial of Aspirin and Arginine Restriction in Colorectal Cancer
Colorectal Cancer
Primary: Rectal Tissue Putrescine Reduction — 17 Participants
N/A N=64 Exploratory Study Of The ERCC-1 Gene
Colon Cancer · Rectal Cancer
Primary: Number of Patients With Excision Repair Cross-complementing Group-1 (ERCC1) Protein Change When Treated With Oxaliplatin — 25 Participants
Phase 2 N=47 Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
Familial Adenomatous Polyposis
Primary: 13-HODE Colonic Tissue Levels — 14.56; 18.83; 23.02; 20.03 ng/mg tissue protein
Phase 2 N=139 Pre-op Rectal ChemoRad +/- Cetuximab
Rectal Cancer
Primary: Percentage of Pathologic Response Rate (pCR) With 95% Confidence Interval. — 26.6; 26.7 percentage of participants
N/A N=2,600 The National CT Colonography Trial
Colorectal Cancer
Primary: Number of Participants With Advanced Adenomas (>=10mm) as Determined by Colonoscopy (Per Patient) — 109; 2422 Participants
N/A N=15 PET-MRI in Diagnosing Patients With Colon or Rectal Cancer
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IIA Colon Cancer
Primary: Maximum Standardized Uptake Value (SUVmax) in Physiologic Regions and Fluorodeoxyglucose (FDG) Avid Lesions in Participants Where PET-CT Was Performed Prior to the…
Phase 2 N=11 PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO)
Colorectal Cancer
Primary: Number of Participants With Treatment Related Adverse Events — 0; 0 Participants
Phase 3 N=175 Colorectal Cancer Metastatic
Colorectal Cancer Metastatic
Primary: Percentage of Participants With Adverse Events (AEs) — 100.00; 40.6; 21.1; 9.1 Percentage of participants
Phase 2 N=45 Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
Adenomatous Polyp · Recurrent Colon Cancer · Recurrent Rectal Cancer
Primary: Change in ACF pERK Levels
Phase 3 N=566 Low-Literacy Physician-Patient Intervention Promoting Colorectal Cancer Screening
Colorectal Cancer
Primary: Colorectal Cancer (CRC) Screening Completion — 17; 69 participants — p=0.32